Ortho Biotech: Don't restrict coverage of antianemics
June 25, 2007
The Bridgewater, N.J., firm maintains that cancer patients could be hurt by CMS' reduced coverage proposal for these antianemia agents.
Like Amgen, Ortho Biotech has taken issue with CMS' proposal to limit coverage of erythropoiesis-stimulating agents (ESAs). Ortho Biotech said CMS should pay heed to what the FDA has approved in its product labeling. The Bridgewater, N.J., firm maintains that cancer patients could be hurt by CMS' reduced coverage proposal for these antianemia agents, adding that others, such as medical associations, health professionals, and patients, have come to the same conclusion. To view the full statement from the maker of Procrit (epoetin alfa), check out
